Vaxcyte (PCVX) PT Raised to $163 at Mizuho

Mizuho analyst Salim Syed raised the price target on Vaxcyte (NASDAQ: PCVX) to $163.00 (from $113.00) while maintaining a Outperform rating.

The analyst commented: "We are updating our PCVX model post the positive Ph1/2 top-line readout of VAX-31 in adults. We maintain an Outperform rating and increase our PT from $113 to $163. Please email us for a copy of our updated model in Excel, if you'd like it."

You May Also Be Interested In

• Viking Holdings (VIK) PT Raised to $82 at Mizuho
• Deere (DE) PT Lowered to $728 at UBS as Agricultural Machinery Cycle Gets Closer
• Walmart (WMT) PT Lowered to $125 at JPMorgan, Overweight Rating Maintained as 'Short Case Feels Greedy'